 Amryt Pharma PLCs NASDAQ:AMYT, LON:AMYT new drug application for its potential treatment for epidermolysis bullosa EB has been approved by the US regulator. The Food and Drug Administration FDA accepted Amrtys application for Oleogel-S10 to be approved as a treatment for cutaneous manifestations of junctional and dystrophic EB, which affects adults and young children and for which there is no currently approved treatment. 